USANA Q3 net sales $274.4M, EPS $1.36; reiterates FY2021 outlook

USANA HEALTH SCIENCES INC

2022-Q3 EPS reported $4.68 revenue$919,165,000

Net sales $274.4M (-8% YoY); diluted EPS $1.36 (-6% YoY).
Active customers 576,000 (-11% YoY); Greater China active customers -13% YoY.
Reiterates FY2021 net sales $1.18-$1.20B, EPS $5.80-$6.00; expects ~$130M free cash flow.
Cash $249M, no debt; repurchased 523k shares for $50M, $137M remaining under authorization.
Supply chain disruptions and inflationary pressures continue; product launches delayed to 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.